VEGFA and cancer: In vitro and in vivo studies demonstrated that TTs impair the proangiogenic properties of cancer cells by reducing the expression of vascular endothelial growth factor (VEGF), the essential mitogenic factor for vascular endothelial cells and the key driver of angiogenesis [184,191,192].